ASSESS ALL ALS - Longitudinal Biomarker Study for Symptomatic ALS and Control Participants
view all Clinical Trials
Overview
This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).
Contact
For more information about this trial or to inquire about eligibility, call 215-707-7845 or email [email protected].